![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) Yale University |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000194 |
The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.
Condition | Intervention | Phase |
---|---|---|
Opioid-Related Disorders |
Drug: Cycloserine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind, Placebo Control |
Official Title: | Neurobiology of Opioid Dependence: 3 |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Please contact site for information.
United States, Connecticut | |
VA Connecticut Healthcare System | |
New Haven, Connecticut, United States, 06519 |
Principal Investigator: | Marc I Rosen, M.D. | VA Connecticut Healthcare System |
Study ID Numbers: | NIDA-00191-3, K20-00191-3 |
Study First Received: | September 20, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000194 |
Health Authority: | United States: Federal Government |
Cycloserine Mental Disorders Substance-Related Disorders Disorders of Environmental Origin Opioid-Related Disorders |
Antimetabolites Anti-Bacterial Agents Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Anti-Infective Agents, Urinary Antitubercular Agents Renal Agents Pharmacologic Actions Antibiotics, Antitubercular |